Rick Hawkins, Chief Executive Officer at Lumos Pharma, discusses the company’s focus on finding a novel treatment for pediatric growth hormone deficiency.
Transcription:
My name is Rick Hawkins, and I’m the CEO and Chairman of Lumos Pharma. I’m the original founder of the company. This is a company that’s in the late-stage development of a small molecule. We’re going to report on the results of a global phase IIb trial, and the indication is in pediatric growth hormone deficiency, or PGHD.
I can tell you this growth hormone market is quite large. It’s about a $5 billion global market. Growth Hormone is approved for 11 different rare diseases in different parts of the world. Once again, it has been approved or been used for almost 40 years now. Our innovation is the fact that we have a small molecule. We can give the same patient population, that takes injectable growth hormone, the standard of care. Right now, it’s a daily injection for 7-8 years of these kids’ lives when they get diagnosed with short stature and a non-function or an under-functioning pituitary gland, and they take daily injections for 7-8 years.
You can imagine the innovation we are coming with, and that is a daily oral mini tablet taken once a day, we believe changed the landscape of treatment for this patient population among other growth hormone disorders in the category that currently injectable growth hormone, common growth hormone is used for.
To learn more about growth hormone deficiency and other endocrine disorders, visit checkrare.com/diseases/endocrine-disorders/